JP2017508804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508804A5 JP2017508804A5 JP2016575626A JP2016575626A JP2017508804A5 JP 2017508804 A5 JP2017508804 A5 JP 2017508804A5 JP 2016575626 A JP2016575626 A JP 2016575626A JP 2016575626 A JP2016575626 A JP 2016575626A JP 2017508804 A5 JP2017508804 A5 JP 2017508804A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- weight
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 72
- 229940125904 compound 1 Drugs 0.000 claims description 41
- 239000007962 solid dispersion Substances 0.000 claims description 19
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 17
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 17
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 12
- 208000037844 advanced solid tumor Diseases 0.000 claims description 11
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 10
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 102200069690 rs121913500 Human genes 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 108700028369 Alleles Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 7
- 102200069708 rs121913499 Human genes 0.000 claims description 7
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000004611 spectroscopical analysis Methods 0.000 claims description 6
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 3
- 102200069689 rs121913500 Human genes 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 6
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 1
- 238000010922 spray-dried dispersion Methods 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953480P | 2014-03-14 | 2014-03-14 | |
| US61/953,480 | 2014-03-14 | ||
| PCT/US2015/020346 WO2015138837A1 (en) | 2014-03-14 | 2015-03-13 | Pharmaceutical compositions of therapeutically active compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085619A Division JP2019163278A (ja) | 2014-03-14 | 2019-04-26 | 治療活性化合物の医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508804A JP2017508804A (ja) | 2017-03-30 |
| JP2017508804A5 true JP2017508804A5 (https=) | 2018-04-26 |
| JP6524119B2 JP6524119B2 (ja) | 2019-06-05 |
Family
ID=54072439
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575626A Active JP6524119B2 (ja) | 2014-03-14 | 2015-03-13 | 治療活性化合物の医薬組成物 |
| JP2019085619A Withdrawn JP2019163278A (ja) | 2014-03-14 | 2019-04-26 | 治療活性化合物の医薬組成物 |
| JP2021035053A Withdrawn JP2021088605A (ja) | 2014-03-14 | 2021-03-05 | 治療活性化合物の医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085619A Withdrawn JP2019163278A (ja) | 2014-03-14 | 2019-04-26 | 治療活性化合物の医薬組成物 |
| JP2021035053A Withdrawn JP2021088605A (ja) | 2014-03-14 | 2021-03-05 | 治療活性化合物の医薬組成物 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20170007661A1 (https=) |
| EP (1) | EP3116491B1 (https=) |
| JP (3) | JP6524119B2 (https=) |
| KR (1) | KR102458157B1 (https=) |
| CN (2) | CN112206232A (https=) |
| AU (2) | AU2015229212B2 (https=) |
| BR (2) | BR122023021436A2 (https=) |
| CA (1) | CA2942070A1 (https=) |
| CY (1) | CY1125205T1 (https=) |
| DK (1) | DK3116491T3 (https=) |
| EA (2) | EA034366B1 (https=) |
| ES (1) | ES2881858T3 (https=) |
| HR (1) | HRP20211233T1 (https=) |
| HU (1) | HUE055209T2 (https=) |
| IL (1) | IL247721B (https=) |
| LT (1) | LT3116491T (https=) |
| MA (1) | MA39725B1 (https=) |
| MX (2) | MX2016011865A (https=) |
| NZ (1) | NZ723860A (https=) |
| PH (1) | PH12016501788B1 (https=) |
| PL (1) | PL3116491T3 (https=) |
| PT (1) | PT3116491T (https=) |
| RS (1) | RS62178B1 (https=) |
| SI (1) | SI3116491T1 (https=) |
| SM (1) | SMT202100444T1 (https=) |
| UA (2) | UA129317C2 (https=) |
| WO (1) | WO2015138837A1 (https=) |
| ZA (1) | ZA201606134B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| SG11201803088PA (en) | 2015-10-15 | 2018-05-30 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017123808A1 (en) * | 2016-01-15 | 2017-07-20 | The J. David Gladstone Institutes | Methods of treating disease by metabolic control of t-cell differentiation |
| ES2912909T3 (es) * | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| WO2018085486A1 (en) * | 2016-11-02 | 2018-05-11 | University Of Cincinnati | Compositions and methods for treating patients suffering from glioma or leukemia |
| JP2020506905A (ja) * | 2017-01-20 | 2020-03-05 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液 |
| HUE061207T2 (hu) | 2017-09-22 | 2023-05-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Kristályos szulfamidvegyület |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| MX2021000068A (es) * | 2018-07-06 | 2021-03-25 | Agios Pharmaceuticals Inc | Formas y composiciones farmaceuticas de ivosidenib. |
| US20210069113A1 (en) * | 2019-09-11 | 2021-03-11 | Modavar Pharmaceuticals LLC | Solid unit dosage form for dose individualized drug delivery |
| AR123228A1 (es) | 2020-08-12 | 2022-11-09 | Servier Pharmaceuticals Llc | Formas en estado sólido de un compuesto orgánico |
| ES2972441T3 (es) | 2020-10-02 | 2024-06-12 | Lonza Bend Inc | Acido acético como auxiliar de procesamiento en el secado por pulverización para fármacos básicos |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8343548B2 (en) * | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
| MX2009006806A (es) * | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
| EP2370417A2 (en) * | 2008-11-21 | 2011-10-05 | Millennium Pharmaceuticals, Inc. | Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
| AU2010223919B2 (en) * | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| KR101460095B1 (ko) * | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| US8652534B2 (en) * | 2009-10-14 | 2014-02-18 | Berry Pharmaceuticals, LLC | Compositions and methods for treatment of mammalian skin |
| NZ609490A (en) * | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| CN102827170A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| NZ627096A (en) * | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2014015422A1 (en) * | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2015
- 2015-03-13 BR BR122023021436-6A patent/BR122023021436A2/pt not_active Application Discontinuation
- 2015-03-13 EA EA201691844A patent/EA034366B1/ru unknown
- 2015-03-13 HU HUE15761216A patent/HUE055209T2/hu unknown
- 2015-03-13 NZ NZ723860A patent/NZ723860A/en unknown
- 2015-03-13 CN CN202010472904.XA patent/CN112206232A/zh active Pending
- 2015-03-13 CA CA2942070A patent/CA2942070A1/en active Pending
- 2015-03-13 HR HRP20211233TT patent/HRP20211233T1/hr unknown
- 2015-03-13 SM SM20210444T patent/SMT202100444T1/it unknown
- 2015-03-13 UA UAA202006348A patent/UA129317C2/uk unknown
- 2015-03-13 PL PL15761216T patent/PL3116491T3/pl unknown
- 2015-03-13 EA EA202090098A patent/EA202090098A1/ru unknown
- 2015-03-13 CN CN201580019581.6A patent/CN106163507B/zh active Active
- 2015-03-13 EP EP15761216.9A patent/EP3116491B1/en active Active
- 2015-03-13 ES ES15761216T patent/ES2881858T3/es active Active
- 2015-03-13 RS RS20210962A patent/RS62178B1/sr unknown
- 2015-03-13 LT LTEP15761216.9T patent/LT3116491T/lt unknown
- 2015-03-13 PT PT157612169T patent/PT3116491T/pt unknown
- 2015-03-13 MA MA39725A patent/MA39725B1/fr unknown
- 2015-03-13 SI SI201531665T patent/SI3116491T1/sl unknown
- 2015-03-13 JP JP2016575626A patent/JP6524119B2/ja active Active
- 2015-03-13 WO PCT/US2015/020346 patent/WO2015138837A1/en not_active Ceased
- 2015-03-13 US US15/125,884 patent/US20170007661A1/en not_active Abandoned
- 2015-03-13 BR BR112016021012-3A patent/BR112016021012B1/pt active IP Right Grant
- 2015-03-13 MX MX2016011865A patent/MX2016011865A/es unknown
- 2015-03-13 UA UAA201610408A patent/UA122962C2/uk unknown
- 2015-03-13 AU AU2015229212A patent/AU2015229212B2/en active Active
- 2015-03-13 KR KR1020167027887A patent/KR102458157B1/ko active Active
- 2015-03-13 DK DK15761216.9T patent/DK3116491T3/da active
-
2016
- 2016-09-05 ZA ZA2016/06134A patent/ZA201606134B/en unknown
- 2016-09-08 IL IL247721A patent/IL247721B/en active IP Right Grant
- 2016-09-13 MX MX2021001739A patent/MX2021001739A/es unknown
- 2016-09-13 PH PH12016501788A patent/PH12016501788B1/en unknown
-
2019
- 2019-04-26 JP JP2019085619A patent/JP2019163278A/ja not_active Withdrawn
- 2019-09-18 AU AU2019232825A patent/AU2019232825B2/en active Active
-
2021
- 2021-03-05 JP JP2021035053A patent/JP2021088605A/ja not_active Withdrawn
- 2021-08-02 CY CY20211100687T patent/CY1125205T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508804A5 (https=) | ||
| JP2017508805A5 (https=) | ||
| AU2019246824B2 (en) | Pharmaceutical compositions of therapeutically active compounds and their methods of use | |
| JP6236071B2 (ja) | ブルトン型チロシンキナーゼ阻害剤の結晶形態 | |
| AU2015229212B2 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| CN109069410A (zh) | 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂 | |
| KR20160006668A (ko) | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 | |
| KR20170033358A (ko) | 브루톤 티로신 키나아제 저해제의 신규한 제제 | |
| KR20240087693A (ko) | 암 치료를 위한 비가역적 메닌-mll 억제제인 n-[4-[4-(4-모르폴리닐)-7h-피롤로[2,3-d]피리미딘-6-일]페닐]-4-[[3(r)-[(1-옥소-2-프로펜-1-일)아미노]-1-피페리디닐]메틸]-2-피리딘카르복스아미드의 결정질 형태 | |
| JP2022033783A (ja) | ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 | |
| JP2018509458A (ja) | ブルトン型チロシンキナーゼ阻害剤の共結晶 | |
| JP2013531067A (ja) | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 | |
| CN115776889A (zh) | 用于治疗非小细胞肺癌的egfr tki | |
| CN115279347A (zh) | Ahr抑制剂和其用途 | |
| JP7728872B2 (ja) | 新規な溶出率を示すタダラフィルまたはこの薬学的に許容される塩及びデュタステリドまたはこの薬学的に許容される塩を含む医薬組成物 |